Izumiyama K, Inao T, Goto H, Harada S, Senjo H, Suto K, Hashiguchi J, Ogasawara R, Saga T, Igarashi T, Wakasa K, Kasahara I, Takeda Y, Yamaguchi K, Shigematsu A, Takahata M, Fujimoto K, Haseyama Y, Nagashima T, Sakai H, Kakinoki Y, Kurosawa M, Yokota I, Teshima T. Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group. Haematologica 2024;109(11):3631-3640; https://doi.org/10.3324/haematol.2023.284841.